Product logins

Find logins to all Clarivate products below.


eBook

Drugs to Watch 2024 revisited: Where are they now?

Get the latest on the performance of 2024’s top pharmaceutical breakthroughs

Each year, Clarivate identifies the most anticipated drugs poised to reshape treatment landscapes. But did they live up to expectations?

In this ebook, we revisit the Drugs to Watch from 2024 and uncover:

For each drug we answer:

  • What is its current market and regulatory status?
  • What happened in 2024 / early 2025?
  • Did it meet commercial and clinical expectations?
  • Why did it succeed or fail to meet expectations?
  • What milestones and challenges lie ahead?

Featured drugs include:

  • EYLEA® HD
  • TARPEYO® / Kinpeygo®
  • DATROWAY
  • ALTUVIIIO™
  • CASGEVY™
  • Omvoh™
  • AKEEGA™
  • ABRYSVO™
  • TALVEY™
  • VYLOY
  • and more

What you’ll find inside:

  • Real-world sales performance and adoption trends
  • Phase 3 trial data and label expansion progress
  • Market access updates across the G7 and beyond
  • Competitive positioning vs. emerging rivals
  • Clarivate’s revised forecasts and future outlooks